HIGHLIGHTS
- What: The overall findings may be affected by the dosage used and the duration of use, which requires further investigation. this studies have some limitations that need to be considered when interpreting the results. The study is the first systematic review and meta-analysis aimed at exploring the risk of AD in users of PDE5Is compared to non-users. While the study has notable limitations, it provides valuable insights into the current understanding of the association between PDE5I use and AD.
- Who: Moaz Elsayed Abouelmagd from the Faculty of Medicine, Cairo University, Cairo have published . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.